EXJADE® | Iron Chelation Therapy For Transfusion-Dependent Patients With Chronic Anemias

MENUEfficacy - IntroductionEfficacy - Chelation at Essential SitesEfficacy - Dose-Dependent ChelationEfficacy - Long-Term EfficacyEfficacy - 24-Hour Activity Efficacy - Clinical Trial SummariesSafety - Long-Term Safety ProfileSafety - Side Effect ManagementSafety - Monitoring GuidelinesSafety - Important Safety InformationDosing - Dosing GuidelinesDosing - Dose CalculatorDosing - Serum Ferritin TrackerPatient Types - IntroductionPatient Types - beta-ThalassemiaPatient Types - Myelodysplastic SyndromesPatient Types - Sickle Cell DiseasePatient Types - Other AnemiasPatient Types - IPSS CalculatorCompliance Support - IntroductionCompliance Support - Side Effect ManagementCompliance Support - Educational ToolsExjade Resources - Summary of Resources and ToolsExjade Resources - Related LinksExjade Resources - Mechanism of ActionAbout Iron Toxicity - Iron ToxicityAbout Iron Toxicity - Morbidity and MortalityAbout Iron Toxicity - Screening and MonitoringAbout Iron Toxicity - Managing Iron ToxicityExjade FAQsAbout Novartis OncologyContact UsSite MapTerms of UsePrivacy PolicyCountry Sites - CanadaCountry Sites - GermanyCountry Sites - JapanCountry Sites - NetherlandsCountry Sites - SwitzerlandCountry Sites - United StatesSwiss PIEU SmPCNovartis OncologyPubmedAre You An Exjade Prescriber Seeking Tips For Treatment Success?Are You Considering Exjade And Seeking Compelling Data?Are You A Researcher Seeking Exjade Information Resources?Swiss PIEU SmPCExjade Important Safety Information EXJADE is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adult and pediatric patients (aged 2 years and over). Please click here for Swiss Prescribing Information. Please click here for EU SmPC. Please click here for Exjade Important Safety Information.References: 1. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-3462. 2. Eleftheriou P, Tanner M, Pennel D, Porter JB. Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysis [11th Congress of the European Hematology Association abstract 0999]. Haematologica. 2006;91(s1):366. 3. Wood J, Thompson AA, Paley C, et al. Exjade® reduces cardiac iron burden in chronically transfused beta-thalassemia patients: an MRI T2* study [American Society of Hematology 49th Annual Meeting abstract 2781]. Blood. 2007;110(11):817a. 4. EXJADE Swiss prescribing information. Berne, Switzerland: Novartis Pharma Schweiz Inc; 2008. Disclaimer: This is an international website for EXJADE, and is intended for healthcare professionals outside the U.S. If you are a U.S. resident, please click on the U.S. residents link at the top of this page. The information on this site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located.© 2008 Novartis AG. Use of this website is subject to our Terms of Use. Regardless of underlying anemia, iron toxicity is an inevitable consequence of ongoing transfusion therapy—and chelation is needed
All transfusion-dependent patients with chronic anemias receive excess iron. These patients need to be routinely screened for iron toxicity, and chelation therapy should be initiated when there is clinical evidence of iron toxicity. Chelation guidelines in other anemiasGuidelines for detecting iron toxicity

Serum ferritin1

Liver iron concentration (biopsy or MRI) 2

Guidelines for initiating chelation therapy

After the transfusion of approximately 20 units (about 100 mL/kg of packed red blood cells)1 or

When there is evidence from clinical monitoring that iron toxicity is present; for example, serum ferritin levels >1000 µg/L1

References: 1. EXJADE Swiss prescribing information. Berne, Switzerland: Novartis Pharma Schweiz Inc; 2008. 2. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115(2):239-252. Other anemias patient profilePatient profile: other anemiasSumi, age 24 Suni, Age 24

Clinical history

Aplastic anemia

Chronic iron toxicity due to blood transfusions

Treatment history

Has received transfusion therapy for the past 5 years

9 transfusions over the past 12 months (3600 mL)

Current challenges

Very high iron burden

Serum ferritin: 8415 µg/L

EXJADE efficacy in other anemiasEXJADE provides proven efficacy in patients with a range of anemias Reductions in LIC Demonstrated in Patients with MDS, Diamond-Blackfan Anemia, Other Anemias, and Beta-Thalassemia

Reductions in LIC Demonstrated in Patients with MDS, Diamond-Blackfan Anemia, Other Anemias, and Beta-Thalassemia

Patients who received 20 mg/kg/day had baseline levels of LIC ranging from >7 to 14 mg Fe/g of dry weight; those who received 30 mg/kg/day had baseline levels of >14 mg Fe/g of dry weight. There were no statistical differences in LIC reductions between disease groups.1
Factors that had a significant impact on LIC were transfusional iron intake (lowest in MDS, highest in Diamond-Blackfan anemia) and daily dosing of EXJADE.1
View long-term efficacy with EXJADEView Important safety informationTo learn about EXJADE dosing for all of your patients with chronic anemias, click here. Reference: 1. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.